Bristol-Myers Squibb Company (ETR:BRM)
Germany
· Delayed Price · Currency is EUR | Market Cap | 85.02B |
| Revenue (ttm) | 44.07B |
| Net Income (ttm) | 5.01B |
| Shares Out | n/a |
| EPS (ttm) | 2.47 |
| PE Ratio | 16.96 |
| Forward PE | 7.30 |
| Dividend | 2.26 (5.35%) |
| Ex-Dividend Date | Apr 4, 2025 |
| Volume | 85 |
| Average Volume | 2,619 |
| Open | 42.02 |
| Previous Close | 42.31 |
| Day's Range | 42.02 - 42.02 |
| 52-Week Range | 36.42 - 58.79 |
| Beta | 0.39 |
| RSI | 46.53 |
| Earnings Date | Jul 31, 2025 |
About ETR:BRM
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
News
BioNTech's Deal With Bristol Myers Over BNT-327 May Be Overhyped
Bristol Myers' new cancer partnership is promising, but doesn't change our stance on the stock yet
Bristol Myers' is making a big move into next-generation cancer treatments. But there's still more to prove.
Why BioNTech Stock Soared Today
Bristol Myers Squibb just agreed to shower BioNTech with cash.
Watch CNBC's full interview with Bristol Myers CEO Christopher Boerner
Christopher Boerner, Bristol Myers CEO, joins 'Squawk on the Street' to discuss the company's recent partnership with Biontech, the cost of the deal and much more.
Bristol Myers CEO on Biontech deal: Next new frontier in treatment of cancer
Christopher Boerner, Bristol Myers CEO, joins 'Squawk on the Street' to discuss the company's recent partnership with Biontech, the cost of the deal and much more.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2095975132-53d951c567e846e5b977bfb95efda524.jpg)
BioNTech Stock Jumps on Bristol Myers Squibb Cancer Drug Collaboration
U.S.-listed shares of BioNTech jumped more than 15% Monday morning after the German vaccine maker announced a collaboration with Bristol Myers Squibb.
Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug
BioNTech SE (NASDAQ: BNTX) and Bristol Myers Squibb & Co . (NYSE: BMY) entered into a co-development and co-commercialization agreement . The pact focuses on BioNTech’s investigational bispecific an...
Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race
Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer’s deal announced two weeks earlier.
BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb
Bristol Myers Squibb signs $11bn cancer drug deal with BioNTech
US-German partnership hopes BNT327 will compete with Merck’s bestseller Keytruda
Notable healthcare headlines for the week: AstraZeneca, Eli Lilly, Bristol Myers in focus
Why the stock rally fizzled plus, our latest thinking on Goldman and Bristol Myers
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Bristol-Myers Squibb Company (BMY) Bernstein 41st Annual Strategic Decisions Conference (Transcript)
Bristol-Myers wins EU nod for Opdivo injectable developed with Halozyme
Bristol-Myers Squibb's Painful Pullback Has Triggered Richer Dividend Story - Upgrade To Buy
Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025. The company will take part...
Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo (nivolumab) Across Multiple Solid Tumor Indications
Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved a new Opdivo (nivolumab) formulation associated with a new route of administration (subcutaneous use [SC...
Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
Opdivo is the first and only PD-1 inhibitor approved for subcutaneous (SC) use in the European Union Approval is based on results from the Phase 3 CheckMate -67T clinical trial which demonstrated noni...
Bristol-Myers Squibb: This Undervalued Dog Needs An Option Collar
Bristol-Myers: Among The Cheapest Pharma Names, Now Yielding Above 5%
Bristol-Myers Squibb At ASCO 2025: A Resilient Play Amid Market Turbulence
Bristol Myers Squibb to Present Data at ASCO 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology portfolio and pipeline at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting to be held ...
Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology portfolio and pipeline at the 2025 American Society of Clinical Oncology (ASCO ®) Annual Meeting to be h...
Major US stock indices close today lower as yields rise
The major US stock indices a closing lower on the day. The Dow industrial average was the worst performer with a decline of -1.91%. The top 10 decliners for the day: UnitedHealth Group (UNH): −5.78% N...